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Background: Recent studies have identiﬁed hypertriglyceridemic cystic ﬁbrosis patients (CF-TG). However, whether hypertriglyceridemia is
associated with an altered metabolic proﬁle remains unknown.
Objective: To characterize CF-TG and determine whether triglycerides (TG) levels are associated with metabolic alterations.
Methods: 210 adult CF subjects from the Montreal Cystic Fibrosis Cohort without known diabetes were included in the analysis. All subjects
underwent an OGTT to assess glucose tolerance, insulin secretion (insulin AUC) and insulin sensitivity (Stumvoll index). Fasting lipid proﬁles,
pulmonary function (%FEV1) and BMI were determined. Hypertriglyceridemia (TGN1.7 mmol/L) was observed in 20 CF patients. These subjects
were matched for age, sex and glucose tolerance category with 20 CF patients (CF-normal-TG) and 20 healthy controls that had TG levels below
1.7 mmol/L. Pearson correlations were performed in the complete study sample (n=210) to examine the associations between TG levels and other
parameters.
Results: The prevalence of hypertriglyceridemia was 9.5%. Compared to CF-normal-TG, CF-TG subjects displayed signiﬁcantly higher %FEV1,
insulin AUC (AUC0–120, AUC0–30, AUC30–120), cholesterol levels and a higher ratio of total cholesterol to HDL-cholesterol. Pearson analysis
demonstrated that TG levels were associated with BMI, %FEV1, fasting insulin, insulin AUC0–120 and AUC30–120, Stumvoll index, cholesterol
levels and the ratio of total cholesterol to HDL-cholesterol. All these correlations remained signiﬁcant after correction for BMI except %FEV1.
Conclusion: TG levels are associated with a mild alteration of the metabolic proﬁle. Whether these changes will increase the long-term risk of CF
patients in developing cardiometabolic complications remains to be investigated.
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Cystic fibrosis (CF) is the most common lethal autosomal
disease affecting the Caucasian population with approximately
one case per 3608 live births in Canada in 2000 [1]. With
advances in clinical and nutritional therapy, the life expectancy
of CF patients has gradually increased to reach a median survival
of 37 years [2]. Increased longevity has led to an increasedby Elsevier B.V. All rights reserved.
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diabetes (CFRD). As the life expectancy of CF patients increases,
wemay start to observe additional cardiometabolic complications
[3].
In most CF subjects, first-phase insulin secretion is absent
leading to increased glucose excursions after a glucose load
even in individuals with normal glucose tolerance (NGT) [4]. In
addition, previous studies have reported that some CF patients
displayed dyslipidemia. Figueroa et al. [5] reported that 16%
of CF patients were hypertriglyceridemic whereas Rhodes et al.
[6] found a prevalence of 5%. In addition, a small percentage
of CF subjects displayed hypercholesterolemia (4%) [5]. Dys-
lipidemia is an important predictor of cardiovascular disease
and is associated with an altered metabolic profile including
glucose and insulin levels and insulin resistance [7–10]. Alter-
ations of both glucose and lipid metabolism may favor the
development of cardiometabolic complications in CF subjects
[3]. The aim of this study was to characterize CF adults with
hypertriglyceridemia and determine whether TG levels were
associated with alterations of the cardiometabolic profile.
2. Materials and methods
2.1. Subjects
The Montreal Cystic Fibrosis Cohort was established in
2004 as part of an ongoing systematic screening program to
detect CFRD using the oral glucose tolerance test (OGTT) [4].
The main objective of this prospective ongoing observational
cohort is to study mechanisms leading to glucose intolerance in
adult CF patients as well as the association of pre-diabetic states
with CF outcomes. The Research Ethics Committee of the
Centre hospitalier de l'Université de Montréal (CHUM) and
the Institut de recherches cliniques de Montréal approved the
protocol and all subjects signed a written consent form. At the
time of the analysis for this study (May, 2011), 210 CF subjects
had been enrolled. We recruited 20 NGT control subjects of
comparable age and body mass index (BMI). All subjects were
over 18 years of age. CF patients were excluded if they had an
exacerbation in the previous month, lung transplant, pregnancy,
or had received oral or intravenous steroids therapy. Patients
already diagnosed with CFRD were excluded from the study.
2.2. Subject classification
Hypertriglyceridemia was defined as TG concentrations
N1.7 mmol/L (150 mg/dL) according to the Canadian
Cardiovascular Society Guidelines [8]. Hypertriglyceridemic
CF (CF-TG) patients were matched with the nearest-aged CF
patients with normal TG (CF-normal-TG) subjects of the same
sex and glucose tolerance category and were compared to
healthy control subjects without CF or hypertriglyceridemia.
2.3. Clinical protocol
Pulmonary function was measured by spirometry on the day
of the OGTT using forced expiratory volume in 1 sec (L/s)(FEV1) and predicted %FEV1 (Medgraphic 1870, St. Paul, MN,
USA). Genotype status and pancreatic insufficiency were ex-
tracted from the medical files. To calculate BMI (kg/m2), body
weight and standing height were measured using an electronic
scale (Tanita Corporation, Arlington Heights, IL, USA) and a
wall stadiometer, respectively.
2.4. Oral glucose tolerance test (OGTT)
All subjects underwent a 2-h OGTT. After an overnight fast,
they ingested in less than 5 min, a glucose solution of 1.75 g/kg
of body weight to a maximum of 75 g and glucose tolerance
categories were determined according to the Canadian Diabetes
Association Guidelines [11]. Blood samples were taken at 0, 30,
60, 90, and 120 min to measure plasma glucose and insulin
levels. Plasma glucose concentrations were measured immedi-
ately in duplicate by the glucose oxidase method (YSI Glucose
Analyzer 2, YSI Incorporated Life Sciences, Yellow Springs, OH,
USA). Insulin levels were quantified in duplicate using a human
insulin radioimmunoassay (Linco Research, Inc., St-Charles,
MO, USA).
2.5. Insulin secretion and insulin sensitivity assessment
The area under the curve (AUC) for both glucose and insulin
was calculated with Graph Pad Prism 4.0 for Windows. We
used insulin AUC0–120, AUC0–30 and AUC30–120 as indices
for total, early and late insulin secretion respectively [12].
Insulin sensitivity was calculated with the Stumvoll index
2001 (0.156−0.0000459∗ Ins120 (pmol/L)−0.000321∗ Ins0
(pmol/L)−0.00541∗Glyc120 (mmol/L)) [13].
2.6. Biochemical dosages
TG, total cholesterol, and HDL-cholesterol were measured
from fasting blood samples by enzymatic reaction (ADVIA1650,
Bayer Health Care Diagnostics). LDL-cholesterol was calculated
from the Friedewald equation [14]. LDL-cholesterol was not
calculated for one individual because their TGwasN4.5 mmol/L.
In the absence of other cardiovascular risk factors, the
Canadian Cardiovascular Society recommends the following
values to define a healthy lipid profile: TGb1.7 mmol/L,
total cholesterolb5.17 mmol/L, LDL-cholesterolb5 mmol/L,
HDL-cholesterolN1.03 mmol/L for men and N1.30 mmol/L for
women.
2.7. Statistical analysis
Data are presented as mean±standard deviation (SD). TG,
fasting insulin, glucose AUC and insulin AUC (0–30; 30–120;
0–120) failed the Levene's homogeneity test of variance and
were log transformed for the analysis. Group comparisons were
performed by independent t-test and one-way ANOVA followed
by LSD post-hoc test as appropriate. The association between TG
levels and other variables were analyzed by Pearson correlation.
We used SPSS for Windows (Version 16.0 SPSS, Chicago, IL)
for statistical analysis. Significance was accepted at pb0.05.
Table 2
Characteristics of control and cystic fibrosis (CF) patients with normal triglyceride
levels (CF normal-TG) and CF patients with hypertriglyceridemia (CF-TG).
Characteristics Control
N=20
CF normal-TG
N=20
CF-TG
N=20
Age (years) 26±4 26±8 26±9
BMI 22.2±1.8 21.0±2.3 22.7±3.9
%FEV1 (L/s) – 67.2±22.6 82.6±23.6*
Sex (men/women) 8/12 6/14 6/14
Pancreatic insufficiency (%) – 75% 75%
Genotype
Δ508 homozygote 15 9
Δ508 heterozygote 3 7
Other mutations 2 4
Glucose tolerance category
Normal 6 6
Intolerance 10 10
Cystic fibrosis-related diabetes 4 4
Values are mean±SD.
BMI: body mass index, %FEV1: predicted forced expiratory volume in 1 s.
pb0.05.
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3.1. Subjects characteristics
Baseline characteristics of the 210 CF subjects included in
the study are presented in Table 1. TG levels above 1.7 mmol/L
were found in 20 patients (9.5% of the cohort), 12 patients
(5.7% of the cohort) had elevated total cholesterol concentra-
tions (N5.17 mmol/L) while three patients had both elevated
TG and total cholesterol levels (1.4% of the cohort).
The 20 CF-TG patients were then matched for age, sex, and
glucose tolerance category with CF patients with normal TG
levels (CF-normal-TG) and with healthy NGT controls for sex
and age. As shown in Table 2, CF-TG and CF-normal-TG
subjects displayed similar genotype, enzyme supplementation,
and BMI. On the other hand, CF-TG showed an 18% higher
%FEV1 compared to CF-normal-TG subjects.
3.2. Lipid profile
As shown in Table 3, levels of HDL and LDL cholesterol
were similar among the three groups. On the other hand, CF
normal-TG subjects displayed lower total cholesterol levels
than either CF-TG or control subjects while CF-TG subjects
showed a higher ratio of total cholesterol to HDL cholesterol
compared to CF normal-TG and control subjects.
3.3. Plasma glucose and insulin profiles during OGTT
CF-TG subjects presented significantly higher fasting glucose
levels compared to control subjects (Table 3). As illustrated inTable 1
Baseline descriptive characteristics of cystic fibrosis subjects (n=210).
Characteristics Mean±SD Range
Age (years) 26±8 18–52
FEV1% (L/s) 73±22 19–119
Sex (% women) 46.6
Genotype
Δ508 homozygote (%) 47.3
Δ508 heterozygote (%) 39.8
Other mutations (%) 10.9
Glucose tolerance category
Normal (%) 57.1
Intolerant (%) 28.3
Cystic fibrosis related diabetes (%) 14.6
Pancreatic insufficiency (%) 79.9
Body mass index (kg/m2) 22.3±3.0 13–31
Fasting glucose (mmol/L) 5.0±0.9 3.0–9.0
Glucose area under the curve 470±229 89–1199
Fasting insulin (μU/ml) 10.0±4.2 2.0–36.5
Insulin area under the curve 3622±2141 416–11906
Stumvoll index 0.08±0.02 0.02–0.13
Triglycerides (mmol/L) 1.08±0.58 0.35–5.05
Cholesterol (mmol/L) 3.54±0.96 1.72–7.06
HDL cholesterol (mmol/L) 1.20±0.31 0.59–2.28
LDL cholesterol (mmol/L) 1.85±0.77 0.63–4.87
Cholesterol/HDL cholesterol 3.02±0.73 1.6–5.6
%FEV1: predicted forced expiratory volume in 1 s.Fig. 1A, both CF-TG and CF normal-TG subjects had similar
glucose excursions during the OGTT. They also exhibited sig-
nificantly higher glucose excursions compared to controls as
highlighted by their higher glucose AUC (Table 3). Next, we
examined insulin levels and insulin AUC. As shown in Table 3,
there was no significant difference in fasting insulin levels be-
tween controls, CF normal-TG and CF-TG. Compared to con-
trols, CF-TG subjects display a 48% decrease in insulin AUC0–30
but similar insulin AUC30–120 and insulin AUC0–120 (Fig. 2A).
Comparison of insulin AUC among CF groups showed that
CF-TG showed a 71%, 74%, and 73% increase in insulin AUC0–30,
AUC30–120, and AUC0–120 respectively compared to CF
normal-TG. We next examined insulin sensitivity using the
Stumvoll index. As shown in Fig. 2B, control subjects displayed
a higher insulin sensitivity index then either CF-TG or CF
normal-TG patients. While we observed slightly lower insulin
sensitivity in CF-TG compared to CF normal-TG, this difference
did not reach significance (p=0.1).Table 3
Metabolic characteristics of control and cystic fibrosis (CF) patients with normal
triglyceride levels (CF normal-TG) and CF patients with hypertriglyceridemia
(CF-TG).
Characteristics Control
N=20
CF normal-TG
N=20
CF-TG
N=20
Triglycerides (mmol/l) 0.87±0.32 0.78±0.29 2.39±0.75 ⁎, §
Fasting glucose (mmol/l) 4.8±0.6 5.3±0.5 5.34±0.5 §
Glucose area under curve 158±71 533±229 § 500±177 §
Fasting insulin (μU/ml) 12.4±6.0 9.7±2.7 12.3±5.1
Total cholesterol (mmol/l) 4.05±0.55 3.38±0.98 §, ¥ 4.16±0.96
HDL-cholesterol (mmol/l) 1.47±0.39 1.26±0.32 1.25±0.36
LDL-cholesterol (mmol/l) 2.19±0.58 1.76±0.80 1.89±0.82
Ratio total cholesterol /HDL 2.9±0.9 2.7±0.6 3.5±0.7 ⁎
HDL: high-density lipoprotein, LDL: low-density lipoprotein.
§ pb0.05 compared to control.
⁎ pb0.05 compared to CF normal-TG.
¥ pb0.05 compared to CF-TG.
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Fig. 1. Plasma glucose (A) and insulin (B) profile in control, cystic fibrosis
patients with normal TG levels (CF) and cystic fibrosis patients with TG above
1.7 mM (CF-TG).
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Fig. 2. (A) Insulin area under the curve (AUC) in control, cystic fibrosis patients
with normal TG (CF) and cystic fibrosis patients with TG above 1.7 mM
(CF-TG). *pb0.05. (B) Stumvoll index of insulin sensitivity in control, cystic
fibrosis subjects with normal TG (CF) and cystic fibrosis subjects with TG
above 1.7 mM (CF-TG). *pb0.05.
Table 4
Pearson correlation of triglycerides with clinical and metabolic factors in cystic
fibrosis subjects (n=210).
Variables r Model corrected for BMI
Age −0.03 −0.03
BMI 0.17 ⁎ –
%FEV1 0.16 ⁎ 0.13
Total cholesterol 0.35 ⁎ 0.33 ⁎
HDL-cholesterol 0.00 0.02
LDL-cholesterol 0.15 ⁎ 0.10
Cholesterol/HDL cholesterol 0.37 ⁎ 0.35 ⁎
Fasting glucose 0.12 0.01
Glucose AUC 0.02 0.03
Fasting insulin 0.26 ⁎ 0.18 ⁎
Insulin AUC0–120 0.20 ⁎ 0.20 ⁎
Insulin AUC0–30 0.14 0.14
Insulin AUC30–120 0.20 ⁎ 0.20 ⁎
Stumvoll −0.29 ⁎ −0.22 ⁎
BMI: body mass index, %FEV1: predicted forced expiratory volume in 1 s.
⁎ pb0.05.
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and insulin secretion and insulin sensitivity, we used Pearson
correlations in the complete study sample (n=210). As shown in
Table 4, TG levels were not associated with age. On the other
hand, they were positively associated with BMI, %FEV1, total
cholesterol levels, total cholesterol to HDL cholesterol ratio,
fasting insulin, insulin AUC0–120 and AUC30–120 but not with
insulin AUC0–30. In addition, we observed a negative correla-
tion between the Stumvoll index of insulin sensitivity and TG
levels. Because TG levels correlated with BMI, we examined
whether these associations were maintained after correction for
this variable. After correction, all variables remains significantly
associated with TG levels except for %FEV1.
4. Discussion
The aim of our study was to determine whether hypertri-
glyceridemia in CF subjects was associated with an alteration
of their cardiometabolic profile. Our study demonstrated that
CF-TG subjects have higher total cholesterol and total choles-
terol to HDL cholesterol ratio as well as higher insulin secretion
as assessed by insulin AUC (AUC0–120, AUC0–30, AUC30–120)
compared to CF normal-TG. Further analysis of the completeCF study sample (n=210) highlighted an association with the
same variables as well as with fasting insulin levels and the
Stumvoll index. Together, these results suggest that in adult
CF patients, hypertriglyceridemia is associated with mild but
significant alteration of the metabolic profile compared to CF
normal-TG. Whether these changes will increase the long-term
risk of CF patients to develop cardiometabolic diseases and
their complications remains to be investigated.
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of the cohort) had elevated TG levels. This is similar to other
studies who reported a prevalence between 5 and 15% depending
on the cut off used to define hypertriglyceridemia [5,6]. Fur-
thermore, and similar to previous studies [5,6], hypertriglyc-
eridemia was unrelated to genotype, glucose tolerance category,
fasting glucose and glucose AUC. Interestingly, CF-TG patients
displayed higher total cholesterol levels as well as a higher
ratio of total cholesterol to HDL-cholesterol compared to CF
normal-TG. We also found a positive relationship between TG
levels and both parameters in our study sample (n=210). Similar
associations have in also been reported in the Physicians Health
Study [15] and in CF subjects [5]. Despite this correlation, the
prevalence of combined hypertriglyceridemia and hypercholes-
terolemia was low in our cohort (1.4% in the study sample).
Both hypertriglyceridemia and the ratio of total cholesterol/
HDL-cholesterol are independent risk factor for the develop-
ment of cardiovascular disease [7–10,16]. However, whether
this also applies to CF subjects remains to be demonstrated
since no deaths from cardiovascular disease have been reported
in this population. However, subclinical changes in left ven-
tricular function have been observed in CF patients [17] and it
has been suggested that CF subjects may have a higher risk of
ischemic heart disease [18,19]. Since the life expectancy of CF
patients is increasing, it is possible that additional complica-
tions will emerge from this population.
CF-TG shown an 18% higher %FEV1 compared to those
with normal TG levels. We also observed that TG levels were
associated with %FEV1 in the complete study sample (n=210).
However, this association did not remain significant after
correction for BMI suggesting that TG levels do not directly
affect lung function but there is no definite proof at this point. It
should be noted, however, that in CF patients, the absence of a
correlation between lung function and TG levels has also been
reported by others [5,20].
We observed an increase in insulin AUC in CF-TG subjects
compared to CF normal-TG subjects. We also observed a
positive correlation between TG levels and insulin AUC30–120
and AUC0–120 but not between TG levels and insulin AUC0–30
in the complete study sample. It is well known that most CF
subjects present delayed first phase insulin secretion [4,21,22].
The absence of a correlation between TG levels and insulin
AUC0–30 may reflect the inability of the beta cells to adapt
first phase insulin secretion to the metabolic state. In contrast
to our results, Figueroa et al. [5] had reported similar insulin
AUC0–120 between CF-TG and CF subjects. However, the age
of the study participants differ significantly between the two
cohorts as our study included only adult subjects whereas in the
study of Figueroa et al. [5], half of the hypertriglyceridemic
subjects were under 19 years old. Potentially, the difference
observed between the two studies could be due to the age of the
subjects included in the analysis.
Numerous studies have highlighted an association between
insulin sensitivity and TG levels [23–25]. Our results demonstrat-
ed that CF-TG subjects displayed higher insulin AUC (AUC0–120;
AUC0–30; AUC30–120) but similar glucose AUC compared to
CF-normal-TG patients suggesting insulin resistance. This resultprompted us to further examine this relationship in CF patients.
Using the Stumvoll index, we did not observe any significant
difference in insulin sensitivity between CF-TG and CF normal-
TG groups. However, because the analysis involved a limited
number of subjects (n=20) we may not have had the power to
detect differences in insulin sensitivity among groups. On the
other hand, using Pearson correlation, we found a negative asso-
ciation between TG levels and insulin sensitivity in the complete
CF study sample and this association was independent of BMI.
This latter result suggests that, similar to what has been observed
in other populations such as type 2 diabetic patients, hypertriglyc-
eridemia is associated with increased insulin resistance in CF
subjects. Further studies are needed to examine this relationship in
the CF population.
Insulin plays an important role in lipid metabolism by
activating lipoprotein lipase, the key enzyme in adipose tissue
TG storage [26,27]. Reduction of enzyme activity following
insulin deficiency or insulin resistance impairs this process
leading to increased TG levels. Moran et al. [28] have previously
shown that insulin-mediated inhibition of lipolysis in CF patients
tends to be diminished compared to controls suggesting insulin
resistance. Our results demonstrated that CF-TG patients display
higher insulin AUC than CF normal-TG subjects. Furthermore,
we also observed a positive association between TG levels and
insulin AUC in all CF patients. Thus, CF-TG subjects represent
a subgroup of patients that are able to increase insulin levels,
potentially to palliate insulin resistance.
This is a cross-sectional study. Therefore, causal associations
between TG and other parameters cannot be made. We included
only CF subjects with de novo diabetes to avoid confounding
factors such as insulin treatment as well as CF subjects with mild
to moderate lung disease. Therefore, whether our findings can be
extended to more severely affected CF subjects remain to be
investigated. Despite these limitations, our results are strengthened
by the use of standard techniques for the evaluation of various
metabolic risk factors in a relatively large, well-characterized
cohort of CF patients.
In conclusion, the present study provides new evidence of an
association of TG levels with insulin AUC and insulin sensitivity
in a population of adult CF subjects with mild to moderate lung
disease. In CF, hypertriglyceridemia is also associated with mild
but significant cardiometabolic abnormalities. Further studies
should examine the long-term significance of theses associations.
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